| Symbol | BIVI |
|---|---|
| Name | BIOVIE INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 680 W NYE LANE,SUITE 204, CARSON CITY, Nevada, 89703, United States |
| Telephone | +1 775 - 888-3162 |
| Fax | — |
| — | |
| Website | https://www.bioviepharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001580149 |
| Description | BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. Additional info from NASDAQ: |
BioVie Inc. - BioVie Announces Update toParkinson’s Phase 3 Development Program
Read moreNew Form SCHEDULE 13G - BIOVIE INC. <b>Filed:</b> 2026-09-03 <b>AccNo:</b> 0001595888-26-000114 <b>Size:</b> 926 KB
Read moreBioVie Inc. - BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Read moreBioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Read morePalumbo Joseph M 🟢 acquired 4.8K shares of BIOVIE INC. (BIVI) at $2.16 Transaction Date: Aug 28, 2026 | Filing ID: 000383
Read moreDirector Chappell Amy Suzon 🟢 acquired 727 shares of BIOVIE INC. (BIVI) at $2.16 Transaction Date: Aug 28, 2026 | Filing ID: 000382
Read moreKIM JOANNE WENDY 🟢 acquired 2.5K shares of BIOVIE INC. (BIVI) at $2.18 Transaction Date: Aug 28, 2026 | Filing ID: 000379
Read moreDirector DO CUONG V 🟢 acquired 15.2K shares of BIOVIE INC. (BIVI) at $2.08 Transaction Date: Aug 27, 2026 | Filing ID: 000378
Read moreNew Form SCHEDULE 13G - BIOVIE INC. <b>Filed:</b> 2026-08-19 <b>AccNo:</b> 0001094891-26-000281 <b>Size:</b> 6 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06847191 | NE3107 in Adults With Neurological Symptoms of Long COVID | Phase2 | Long COVID | Active_Not_Recruiting | 2025-04-29 | 2026-09-01 | ClinicalTrials.gov |
| NCT06757010 | A Study of NE3107 in Early Parkinson's | Phase2 | Parkinsons Disease (PD) | Completed | 2025-03-26 | 2026-05-31 | ClinicalTrials.gov |
| NCT05970575 | Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Trau… | Phase2 | Traumatic Brain Injury | Terminated | 2023-12-21 | 2025-07-21 | ClinicalTrials.gov |
| NCT05227820 | Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatmen… | Phase2 | Alzheimer Disease | Completed | 2022-01-19 | 2022-08-20 | ClinicalTrials.gov |
| NCT05083260 | NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa | Phase1 | Parkinson Disease | Completed | 2022-01-04 | 2023-01-04 | ClinicalTrials.gov |
| NCT04669028 | A Phase 3 Study of NE3107 in Probable Alzheimer's Disease | Phase3 | Alzheimer Disease | Completed | 2021-08-05 | 2023-10-25 | ClinicalTrials.gov |
| NCT04112199 | A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patient… | Phase2 | Ascites | Terminated | 2021-06-17 | 2023-05-08 | ClinicalTrials.gov |
| NCT03107091 | Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Asc… | Phase2 | Cirrhosis | Completed | 2017-07-15 | 2019-04-25 | ClinicalTrials.gov |
| NCT01700452 | Diagnostic Study for Lung Cancer Detection Test | — | Lung Cancer | Completed | 2012-04-01 | 2016-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Long COVID | ACTIVE_NOT_RECRUITING | NCT06847191 |
| NE3107 | Other | Phase PHASE2 | Long COVID | ACTIVE_NOT_RECRUITING | NCT06847191 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | COMPLETED | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | COMPLETED | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Long COVID | ACTIVE_NOT_RECRUITING | NCT06847191 |
| NE3107 | Other | Phase PHASE2 | Long COVID | ACTIVE_NOT_RECRUITING | NCT06847191 |
| placebo | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT05083260 |
| NE3107 | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT05083260 |
| Terlipressin acetate continuous infusion | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03107091 |
| Placebo | Other | Phase PHASE3 | Alzheimer Disease | COMPLETED | NCT04669028 |
| NE3107 | Other | Phase PHASE3 | Alzheimer Disease | COMPLETED | NCT04669028 |
| BIV201 continuous infusion | Other | Phase PHASE2 | Ascites | TERMINATED | NCT04112199 |
| NE3107 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT05227820 |
| NE3107 | Other | Phase PHASE2 | Traumatic Brain Injury | TERMINATED | NCT05970575 |
| Placebo | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT06847191 |
| NE3107 | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT06847191 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| placebo | DRUG | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT05083260 |
| Placebo | DRUG | Phase PHASE2 | Long COVID | RECRUITING | NCT06847191 |
| NE3107 | DRUG | Phase PHASE2 | Long COVID | RECRUITING | NCT06847191 |
| BIV201 continuous infusion | DRUG | Phase PHASE2 | Ascites | TERMINATED | NCT04112199 |
| Terlipressin acetate continuous infusion | DRUG | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03107091 |